LUYE PHARMA (02186): Innovative Drug Ruoxinlin Approved in China for a New Indication for the Treatment of Generalized Anxiety Disorder

date
19:33 19/11/2026
avatar
GMT Eight
LUYE PHARMA (02186) announced that Ruoxinlin (Toludesvenlafaxine Hydrochloride Extended-Release Tablets), a Class 1 innovative drug independently developed by the Group, has been approved by the National Medical Products Administration for the treatment of generalized anxiety disorder. To the Company's knowledge, this product is China's first independently developed innovative chemical anxiolytic drug with proprietary intellectual property rights, marking a major breakthrough for China's original innovative drugs in this therapeutic area.
LUYE PHARMA (02186) announced that the Group's independently developed Class 1 innovative drug Ruoxinlin (Toludesvenlafaxine Hydrochloride Extended-Release Tablets) has been approved by the National Medical Products Administration for the treatment of generalized anxiety disorder. To the Company's knowledge, this product is China's first independently developed anxiolytic chemical innovative drug with independent intellectual property rights, marking a major breakthrough for China's original innovative drugs in this therapeutic field. Ruoxinlin was first approved for marketing in China in November 2022 for the treatment of depression. The newly approved indication of generalized anxiety disorder is the second indication obtained by this product in China. Ruoxinlin is China's first and currently only serotonin (5-HT), norepinephrine (NE), and dopamine (DA) triple reuptake inhibitor (SNDRI). Clinical studies have confirmed that the product can rapidly and comprehensively improve anxiety symptoms, with high response and remission rates, significantly promoting the improvement of patients' overall condition and the recovery of social functioning, with good overall safety and tolerability, bringing a differentiated new treatment option to patients with generalized anxiety disorder.